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Introduction 
Leukemia cutis (LC) represents infiltration of the skin 
by malignant leukocytes and it is usually associated 
with a poor prognosis [1]. Depending on the type of 
leukemia, cutaneous involvement varies widely and 
is estimated between 3% to 30% [2]. Leukemia cutis 
typically presents as firm, red-brown papules and 
nodules with a predilection for the head, neck, and 
trunk. The bullous clinical subtype is considered a 
rare entity and can be a diagnostic challenge [1]. 
Herein, we describe a patient with bullous LC 
mimicking vesiculobullous skin disease. 
 
Case Synopsis 
A 62-year-old man with a history of acute 
myelogenous leukemia (AML) presented to the 
emergency room with a progressive asymptomatic 
eruption on the face, neck, and extremities including 
red-brown papules and nodules with tense clear and 
hemorrhagic bullae. Bullae affected areas of the skin 
with nodules as well as normal skin (Figures 1-3). 
The patient reported he was otherwise well. 
Intravenous acyclovir and airborne precautions were 
initiated for a presumed diagnosis of disseminated 
zoster. Acyclovir therapy had no beneficial effect and 
he continued to develop new lesions subsequently. 
Blood cultures, multiple viral PCR swabs, and 
bacterial swabs were negative. When assessed by the 
dermatology team the patients hemoglobin was 
80g/L (normal range 130-180g/L), white blood count 
15.7×109/L (normal range 4-11×109/L), and platelets 
Abstract 
Leukemia cutis represents infiltration of the skin by 
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Figure 1. Red-brown papulonodules and tense clear and 
hemorrhagic bullae overlying normal skin as well as existing 
nodules on the head and neck. 
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8×109/L (normal range 150-400×109/L) with no 
neutropenia or eosinophilia. 
The patient’s medical history was significant for 
refractory AML (80% blasts, normal karyotype, NPM1 
negative with low FLT3) that had not achieved 
remission despite induction chemotherapy and 
reinduction chemotherapy five months prior. He 
continued to receive supportive care and 
hydroxyurea for count control. 
At the time of this presentation there were no other 
sites of extramedullary disease. There were no new 
medications introduced. There was no personal or 
family history of autoimmune vesiculobullous 
diseases. Our differential diagnosis included 
autoimmune vesiculobullous diseases, paraneo-
plastic pemphigus, bullous Sweet syndrome, 
erythema multiforme, bullous drug eruption, and 
infectious etiologies. 
A pink, well-defined papulonodule with an overlying 
tense vesicle on the upper right arm was selected for 
 
Figure 2: Red-brown papulonodules and hemorrhagic vesicles 
and bullae on the patient’s forehead and eyelids. 
 
Figure 3. A solitary, non-inflammatory, tense bulla on the 
patient’s arm. 
 
Figure 4. H&E sections of the skin lesion show a subepidermal 
bullae with background dense superficial and deep perivascular 
and interstitial infiltrate of atypical mononuclear tumor cells. 
There is background spongiosis, brisk dermal edema and 
extravasated red blood cells. There are patchy foci of fragmented 
nuclei throughout. There is no vasculitis. 
 
Figure 5. On higher power, tumor cells have enlarged nuclei, 
moderate amounts of eosinophilic cytoplasm, fine dispersed 
chromatin and variably prominent nucleoli, H&E. 
Immunohistochemically, tumor cells are positive for CD43 (inset 
top right) and CD33 (inset bottom right); magnifications same as 
H&E. Tumor cells were negative for CD34, CD117 (not shown). 
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biopsy. Two skin biopsies were completed from this 
site: a lesional biopsy for routine hematoxylin and 
eosin and a perilesional normal-appearing site for 
direct immunofluorescence. A skin biopsy for culture 
was not performed. The direct immunofluorescence 
was negative for IgM, IgG, IgA, and C3. 
Histopathology showed a brisk atypical 
mononuclear interstitial and perivascular infiltrate 
(superficial and deep) with subepidermal bulla 
formation (Figures 4, 5). There was no evidence of 
viral cytopathic effect and no organisms were seen. 
Immunohistochemically, atypical mononuclear cells 
were positive for CD43 and CD33 and negative for 
CD34, MPO, and CD117, consistent with a cutaneous 
leukemic deposit (Figures 4, 5). No additional 
histological or immunohistological stains were 
performed. Taken together, the dermatologic and 
pathologic findings were consistent with a diagnosis 
of bullous LC with hemorrhage. Airborne 
precautions were discontinued after a two-week 
time period post-initiation. One month later at follow 
up, the patients lesions persisted. He was offered 
cytarabine by the oncology team for treatment but 
declined any further chemotherapy at this time.  
 
Case Discussion 
In the setting of AML, LC is uncommon and may be a 
presenting sign of the malignancy, either preceding, 
following, or concurrently with the diagnosis of AML 
[1]. Leukemia cutis carries a high mortality rate, 
upwards of 80% at one year post-diagnosis [2]. 
Although the clinical presentation is most frequently 
red-brown papulonodules, as seen in our patient, 
intralesional hemorrhage can often be seen 
secondary to thrombocytopenia [1]. Treating the 
underlying leukemia will resolve the cutaneous 
manifestations [1]. 
A combination of clinical morphology, clinical 
history, and skin biopsy are needed to recognize and 
diagnose LC. Clinically, our aforementioned 
differential diagnosis included autoimmune 
vesiculobullous diseases, paraneoplastic 
pemphigus, bullous Sweet syndrome, erythema 
multiforme, bullous drug eruption, and infectious 
etiologies. Bullous pemphigoid, linear IgA bullous 
dermatosis, and dermatitis herpetiformis were the 
autoimmune vesiculobullous entities under 
consideration in this case. In hindsight, bullous 
pyoderma gangrenosum, bullous arthropod bite 
reaction, and bullous leukocytoclastic vasculitis 
could have also been included in our differential 
diagnosis. 
Although more commonly seen in patients with 
chronic lymphocytic leukemia, a rare entity to keep 
in mind in patients with AML is eosinophilic 
dermatosis of hematologic malignancy [3]. 
Eosinophilic dermatosis of hematologic malignancy 
can appear polymorphic, including a 
papulovesicular presentation. Similarly, this entity 
has also been reported to have been initially 
misdiagnosed as varicella zoster virus [3]. 
The term scabies serrupticius was introduced by 
Cohen in 2017 to encompass all the atypical 
presentations of a scabies mite infestation [4]. One of 
the many subtypes, bullous scabies, can mimick 
autoimmune blistering diseases such as bullous 
pemphigoid [4], making scabies an important 
polymorphous entity to keep in mind in those 
presenting with vesiculobullous lesions.  
Histologically, LC displays atypical leukemic cells in 
the dermis and subcutis in a perivascular, 
periadnexal, and interstitial distribution [2, 5, 12]. A 
Grenz zone (sparing of the upper papillary dermis), 
brisk mitoses, and stromal fibrosis can be also be 
seen [2, 5, 12]. Bullous LC can show subepidermal 
bulla formation, which clinically form tense bulla, as 
seen in our patient (Figures 1-3). In myeloid 
leukemias such as AML, the immunophenotypic 
profile can be positive for CD43, CD33, CD34, and 
CD117 [2, 5, 12]. 
Bullous LC is an unusual variant of LC and therefore 
difficult to diagnose [6-10]. For example, a reported 
patient with CLL had her bullous LC misdiagnosed as 
facial cellulitis [7]. Review of the available 
retrospective studies of patients with LC reflect the 
rarity of the bullous clinical subtype. In two 
retrospective studies totaling 117 patients with LC, 
only three patients were found to have bullous 
lesions [8, 10]. Fifty-three patients with LC from three 
separate retrospective studies were reviewed and 
none presented with the bullous LC variant [2, 11, 12]. 
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Conclusion 
Our case is unique in that it highlights how clinically 
similar the bullous subtype of LC can appear to other 
vesiculobullous diseases. Furthermore, we highlight 
how these similarities can lead to misdiagnosis and 
negative patient sequela, such as being left on  
isolation precautions for prolonged periods of time. 
Thus, it is important for clinicians to be aware of this 
unique clinical subtype. 
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